NCT05035589

The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Sciberras, Stephen M.D. · Individual
• Sex: All
• Age: 16 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This study aims to establish whether tocilizumab has any significant effect on procalcitonin levels on patients diagnosed with COVID-19 pneumonia requiring intensive care admission. The effects on other biochemical and clinical markers are also considered.

Detailed description

A retrospective study, involving the first fifty patients treated with tocilizumab for acute deterioration in COVID-19 pneumonia in the Intensive Care Unit (ICU) at Mater Dei Hospital in Malta. The following parameters will be collected from medical records: * procalcitonin levels, daily for twenty days or until discharge or death. * namely white cell count (WCC), neutrophils, lymphocytes, * C-reactive protein (CRP) * PaO2/FiO2 ratio (P/F ratio). This group will be compared to a control group was chosen from patients admitted to the ICU who were not eligible for tocilizumab treatment, matched to the study group for age, gender, mode of ventilation required and length of stay in ICU.

Conditions

• COVID-19 Pneumonia
• ARDS

Interventions

Type	Name	Description
DRUG	Tocilizumab	Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg

Timeline

• Start date: 2021-09-20
• Primary completion: 2021-10-20
• Completion: 2021-11-20
• First posted: 2021-09-05
• Last updated: 2023-04-11

Locations

1 site across 1 country: Malta